TRPV4 drives the progression of leiomyosarcoma by promoting ECM1 generation and co-activating the FAK/PI3K/AKT/GSK3β pathway
Our findings provide a novel mechanism by which TRPV4 directly activates Ca<sup>2+</sup>/FAK/PI3K/AKT/GSK3β pathway and further indirectly enhances the FAK/PI3K/AKT/GSK3β pathway through the promotion and secretion of ECM1 to promote LMS malignant progression. Targeting the TRPV4/FAK axis might be a promising potential strategy for prognosis and treatment of LMS.
Authors
- Yingying Zhao (ORCID: https://orcid.org/0000-0002-6566-1841)
- Yingyong Hou (ORCID: https://orcid.org/0000-0001-9156-2305)
- Yuhong Zhou (ORCID: https://orcid.org/0009-0009-3297-0873)
- Xi Guo (ORCID: https://orcid.org/0000-0002-3152-0282)
- Zhiming Wang (ORCID: https://orcid.org/0000-0002-2306-8468)
- Rongkui Luo (ORCID: https://orcid.org/0000-0002-4118-7225)
- Zhengqing Song (ORCID: https://orcid.org/0000-0001-5622-9021)
- Qiwen Zhou (ORCID: https://orcid.org/0000-0002-6598-5643)
- You Yang (ORCID: https://orcid.org/0000-0001-9171-986X)
- Jiefeng Cui (ORCID: https://orcid.org/0000-0001-6996-720X)
- Shuxiu Xiao (ORCID: https://orcid.org/0000-0003-3210-486X)
- Yong Zhang (ORCID: https://orcid.org/0000-0002-5831-637X)
- Wei Li (ORCID: https://orcid.org/0000-0002-1732-8999)
- Jiali Qian (ORCID: https://orcid.org/0000-0002-9651-0886)
- Chenlu Zhang (ORCID: https://orcid.org/0000-0002-9810-411X)
- Long‐Sheng Lu (ORCID: https://orcid.org/0000-0002-4247-1981)
- Chuxin Huang (ORCID: https://orcid.org/0000-0003-3649-0497)
- Weiqi Lu
- Hanxing Tong (ORCID: https://orcid.org/0000-0001-5227-3711)
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Suzhou Municipal Hospital (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Xiamen Chang Gung Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1007/s13402-024-01008-7
- Citations
- 4
- Primary Topic
- Ion Channels and Receptors
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- Wu Jieping Medical Foundation